Arbutus Biopharma Corp Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Arbutus Biopharma Corp (ABUS) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $0 as of 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2020-03-05
- 2019-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $0.00.
- 2018-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $12.66M.
- 2017-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $16.94M.
- 2016-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $41.26M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-05 |
| 2018-12-31 | $12.66M 10-K · filed 2020-03-05 |
| 2017-12-31 | $16.94M 10-K · filed 2019-03-07 |
| 2016-12-31 | $41.26M 10-K · filed 2018-03-16 |
| 2015-12-31 | $146.32M 10-K · filed 2017-03-22 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |